By
Iceland-headquartered Embla Medical (formerly Ossur), a Nasdaq Copenhagen listed provider of mobility solutions, has signed an agreement to invest in a majority share (51% of the shares) in privately owned Streifeneder ortho.production. Today Streifeneder ortho.production is part of Streifeneder Group, a supplier of orthopaedic solutions and operator of a large O&P clinic network in Bayern, Germany.
“By joining forces with Embla Medical, we have found the ideal partner for Streifeneder,” said Friedrich Streifeneder, managing director of Streifeneder ortho.production. “Combining the two businesses will secure a leading position in the O&P market.”
Streifeneder is an international developer and supplier of orthopaedic mobility solutions, employing around 100 people. In addition to its offerings of prosthetic and orthotic components, Streifeneder also supplies orthopaedic materials and equipment to the O&P industry. In 2024, Streifeneder realized sales of €25m (US$29m) with approximately 70% of sales related to prosthetics and orthopaedic materials. The majority of sales are generated in Germany, combined with sales into other key European markets and distribution into the Americas and APAC regions.
“The addition of Streifeneder will position us as a full-range solutions provider with opportunities to strengthen our presence in our key markets and expand our reach in Emerging Markets,” said Sveinn Sölvason, president and CEO of Embla Medical.
The majority investment in Streifeneder will also strengthen Embla’s presence in Germany, the second largest O&P market in the world.
Streifeneder is estimated to grow in line with the global prosthetics market in the range of 5-7% in the near-term, in addition to realizing commercial synergies by leveraging Embla Medical/Össur’s global footprint.
Sales for Embla Medical in Q1 2025 amounted to US$203m representing organic growth of 4% driven by a strong finish to the quarter. Ebitda margin for the quarter was 18%; up 1%-point from Q1 2024.
.png "Gaza Fund (1)")
